Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on October 25, 2016. The report details a significant clinical milestone achieved in a study supported by the Company at UCLA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical event rather than financial performance.
Material Changes
The primary material event is the first successful implantation and activation of a wireless visual cortical stimulator in a human subject. A 30-year-old patient was implanted with a wireless multichannel neurostimulation system on the visual cortex and successfully perceived and localized individual phosphenes (spots of light) with no significant adverse side effects.
Guidance, Outlook, and Management Commentary
Management notes that while the device used in this study is not the Company's Orion™ I Visual Cortical Prosthesis, it serves as the initial human proof of concept for the ongoing development of the Orion I. No specific financial guidance or risk factors were disclosed in this specific filing.
Investor Verification Checklist
- Verify the distinction between the experimental device used in the UCLA study and the Company's commercial Orion™ I product.
- Confirm the timeline for future clinical trials based on this proof of concept.
- Review the full text of the press release furnished as Exhibit 99.1 for additional technical details.
- Check subsequent filings for any financial impact or capital requirements related to advancing the Orion I development.